Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) has shared an update.
BeOne Medicines Ltd. has outlined the responsibilities and structure of its Nominating and Corporate Governance Committee. The committee is tasked with identifying qualified individuals for the Board, recommending director nominees, developing corporate governance guidelines, and overseeing annual evaluations of the Board and its committees. Composed entirely of independent directors as per NASDAQ rules, the committee plays a crucial role in maintaining and enhancing the company’s governance framework.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,619,453
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$235.8B
For an in-depth examination of 6160 stock, go to TipRanks’ Stock Analysis page.